Tag Archive for: CYP11A1 inhibitor
UPDATE About ACE-232: Phase 1 Trial of a Novel CYP11A1 Inhibitor for mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxOST11098: A Promising New Approach for Castration-Resistant Prostate Cancer
/0 Comments/in Preclinical Research/by MaxPhase 1 Trial Will Soon Start Recruiting: ACE-232 a Promising Inhibitor of CYP11A1
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 trial of INV-9956: A Promising CYP11A1 Inhibitor Targeting Drug-Resistant Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC AI ai in healthcare alphafold antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus personalized medicine Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- New Bacterial Therapy Destroys Tumors in Immunocompromised Animal Models August 9, 2025
- Phase 2 trial: Tarlatamab for Neuroendocrine Prostate Cancer (NEPC) August 8, 2025
- Phase Ib/II Study of TYK-00540 Combined With Enzalutamide in mCRPC August 8, 2025
- Phase Ib/II Clinical Trial of TY-302 and Abiraterone Acetate in mCRPC August 8, 2025